ArticleThe Journal of cell biology2016

P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.

Ari Hashimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.